|
Impact of RAS status and prior targeted therapy on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in daily practice. Final results of the QoLiTrap prospective non-interventional study. |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Medac; Merck Serono; MSD; Roche; Sanofi; Servier |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; Merck; MSD; Roche; Sanofi; SERVIER |
Research Funding - German Cancer Aid (Inst); Medac (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Janssen; Novartis; Pfizer; Pharmatias; Sanofi |
|
|
Honoraria - AstraZeneca; Janssen |
Travel, Accommodations, Expenses - BMS Brazil |
|
|
Travel, Accommodations, Expenses - Bayer (Inst); Celgene (Inst); Roche (Inst) |
|
|
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Merck; Roche |
|
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Merck; MSD; Pfizer; Pierre Fabre; Roche; SERVIER |
|
Christine Windemuth-Kieselbach |
Employment - CRO Alcedis GmbH which was contracted for statistical analysis by Sanofi Deutscht |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |